Rev-erba inhibits proliferation by reducing glycolytic flux and pentose phosphate pathway in human gastric cancer cells

Linlin Tao¹², Haoyuan Yu¹, Rui Liang¹, Ru Jia¹, Jingjing Wang¹, Kai Jiang¹ and Zhengguang Wang¹

Abstract
Rev-erba is a nuclear receptor, which regulates circadian rhythm, inflammatory responses and lipid metabolism. We previously showed Rev-erba reduction in human gastric cancer, which is associated with TMN stages and poor prognosis. We hypothesized that Rev-erba modulates proliferation via glycolytic flux and the pentose phosphate pathway (PPP) in gastric cancer. Knockdown of Rev-erba significantly increased proliferation as well as glycolytic flux and the PPP in human gastric cancer cells. These effects were reduced by a Rev-erba agonist GSK4112 in a dose-dependent manner. Furthermore, Rev-erba was recruited on the promoters of PFKFB3 and G6PD genes, thereby inhibiting their gene transcription. GSK4112 treatment reduced PFKFB3 and G6PD gene expression, which was not affected by BMAL1 knockdown. Pharmacological inhibition of glycolysis and the PPP using corresponding PFKFB3 and G6PD inhibitors attenuated Rev-erba knockdown-induced proliferation in gastric cancer cells. GSK4112 treatment was not able to reduce proliferation in SGC-7901 overexpressing both PFKFB3 and G6PD genes. Both PFKFB3 and G6PD were overexpressed in patients with gastric cancer, and positively correlated with the TMN stages. The PPP and glycolysis were enhanced in gastric cancer tissues of patients with low expression of Rev-erba compared to the patients with high expression of Rev-erba. In conclusion, Rev-erba reduction causes gastric cancer progression by augmenting the PPP and glycolysis.

Introduction
Gastric cancer is the second most common cause of cancer-related death worldwide¹². Gastric cancer cells rely on aerobic glycolysis instead of oxidative phosphorylation providing bioenergetics and macromolecule synthesis for their proliferation, which is termed ‘Warburg effect’. It has been shown that the levels and/or enzymatic activities of hexokinase II (HKII), phosphofructokinase (PFK), M2 type of pyruvate kinase (PKM2), 6-phosphofructokinase-2/fructose-2,6-bisphosphatase (PFKFB3), and glucose-6-phosphate dehydrogenase (G6PD) involved in glycolysis and pentose phosphate pathway are increased, which results in the progression and/or poor prognosis of gastric cancer³–¹⁰. In fact, reoperative metabolic syndrome is predictive of significant gastric cancer mortality after gastrectomy¹¹. However, the mechanisms underlying these increased enzymes in gastric cancer are not clear.

Rev-erba is a nuclear receptor, which has two members, Rev-erba and Rev-erbb, and serves as receptor for heme. Rev-erba plays a number of diverse and important roles in regulation of circadian rhythm, inflammatory responses, senescence, and lipid in central nervous system and peripheral organs¹²,¹³. There are limited studies regarding the role of Rev-erba in tumors. Rev-erba mRNA levels are significantly reduced in breast cancer cells, while Rev-erbb mRNA expression is significantly increased¹⁴. Activation of Rev-erba/β inhibits breast cancer cell proliferation, and is cytotoxic in cancer cells derived from different tumor
types, namely brain, leukemia, breast, colon and melanoma. Our recent study showed that the expression of Rev-erbα was decreased in human gastric cancer, which was associated with TMN stages and poor prognosis. However, it is unknown whether Rev-erbα modulates glycolysis and subsequent proliferation in gastric cancer cells. We, therefore, hypothesize that Rev-erbα inhibits glycolysis and pentose phosphate pathway, thereby reduces proliferation in gastric cancer cells.

**Materials and methods**

**Cell cultures and treatments**

The human gastric cancer cell lines, including SGC-7901, BGC-823, and AGS, were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). There was no mycoplasma contamination. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing high glucose, L-glutamine, pyridoxine hydrochloride, sodium pyruvate and bicarbonate along with 10% heat inactivated fetal bovine serum (Clark Bioscience, Richmond, VA, USA), 100 U/ml penicillin and 100 µg/ml streptomycin at 37 °C with 5% CO2 in a humidified atmosphere. Cells were transfected with GSK4112 (0.5 µM, Calbiochem) or dehydroepiandrosterone (DHEA, 250 µM) and 250 µM oligomycin, and 50 mM 2-deoxy-D-glucose according to the manufacturer’s instructions. In brief, the cells were incubated with 5′-ethynyl-2′-deoxyuridine (EdU, 10 µM) for 2 h. Cells were then washed and incubated with 3 ml of PBS containing 1% bovine serum albumin (GE Healthcare Life Sciences), which was centrifuged at 1500 × g for 10 min at 4 °C and fixed with 100 µl 4% formaldehyde for 15 min. Cells were then fixed with 100 µl 4% formaldehyde for 15 min. After permeabilization, the samples were incubated with CuSO4 and Alexa Flour® 488 coupled to azide for 30 min, and measured by the flow cytometry with 50,000 events.

**Glycolytic analysis**

XF-24 Extracellular Flux Analyzer (Seahorse Bioscience) was used for real-time analysis of extracellular acidification rate (ECAR). Cells were seeded in Seahorse XF-24 cell culture microplates at the density of 20,000 cells/well. ECAR was recorded followed by sequential injections with 10 mM glucose, 1.0 µM oligomycin, and 50 mM 2-deoxy-D-glucose according to the manufacturer’s manual.
Lactate, glucose and NADPH measurement

Intracellular levels of lactate were determined using lactate assay kit (BioVision, Milpitas, CA) according to the manufacturer’s instructions. Glucose levels in the supernatants were determined using Glucose Colorimetric/Fluorometric Assay Kit (Biovision) according to the manufacturer’s instructions. Glucose consumption was calculated as fold change relative to untreated controls. Intracellular NADPH levels were determined using the NADP/NADPH Quantiﬁcation Kit (Biovision) according to the manufacturer’s instructions.

Immunohistochemistry

Rev-erbα, PFKFB3 and G6PD protein abundance in human gastric normal and cancer tissues was measured by immunohistochemistry22. Briefly, the specimens were blocked with 3% hydrogen peroxide, 10% normal goat serum for 10 min, respectively, and then incubated with their antibodies (1:100–1:250 dilutions, Abcam, USA) overnight at 4 °C. After incubation with biotin-conjugated secondary antibody (PV6000, ZSGB-BIO, China), the tissue slides were incubated with streptavidin-biotin horseradish peroxidase complex followed by incubation with diaminobenzidine (DAB, ZSGB-BIO, China) for 5 min. The counterstaining with hematoxylin was then performed, and the bright-ﬁeld microscope was used to take images of stained samples in a single-blinded manner. The relative protein expression of all images was calculated in the mean optical density (MOD) units. The relative protein expression of all images was calculated in the mean optical density (MOD) units. The staining intensity was scored as 0 (no staining), 1’ (≤ 25%, weakly stained), 2’ (25–50%, moderately stained), or 3’ (≥ 50%, strongly stained). A low REV-ERBα expression was deﬁned as score 0’, 1’ or 2’, and a high REV-ERBα expression was deﬁned as score 3’. The patients divided into two groups: low expression group (n = 43) and high expression group (n = 31) of Rev-erbα as we described16.

Western blot

Cells were lysed in lysis buffer (25 mM HEPES, 2 mM MgCl2, 2 mM DTT, 1 mM EDTA, 1 mM PSMF, 5 µg/ml leupeptin, pH 7.4). Freeze-thawing the suspension liquid containing the extracted protein 3 times subsequently, the lysates were centrifuged at 10,000 rpm at 4 °C for 10 min25. The concentration of extracted protein in supernatants was determined by the BCA assay. The protein extracts (10–20 µg) were separated by 4–12% SDS–PAGE and transferred to polyvinylidene ﬂuoride (PVDF) membranes. Following non-speciﬁc blocking with 5% skimmed milk at room temperature for 2 h, PVDF membrane was washed 3 times with TBST (TBS contained 0.1% Tween-20) for 10 min each time. The membranes were then incubated with antibodies against REV-ERBα (Cat#, ab174309; Abcam), PFKFB3 (Cat#: ab181861, Abcam) and G6PD (Cat#: ab993, Abcam) overnight at 4 °C, and then washed 3 times with TBST for 10 min each time. The membranes were incubated with the corresponding rabbit anti-goat horseradish peroxidase-conjugated secondary antibody (rabbit; cat no. AP106P; 1:5,000 dilution; EMD Millipore) for 2 h at 20 °C, after that washed 3 times with TBST again for 10 min each time. The detection of the molecules of interest was carried out using enhanced chemiluminescence (Beyotime Institute of Biotechnology, Haimen, China). The bands were quantiﬁed to calculate relative protein expression levels using Quantity one software version 4.99.5.2.0 (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

Reverse transcription quantitative polymerase chain reaction (RT-qPCR)

Total RNA was extracted from human tissues and cells using TRIzol® (Life Technologies; Thermo FisherScientiﬁc, Inc.). Total RNA was reverse transcribed by cDNA synthesis using a PrimeScript RT Reagent kit with gDNA Eraser (Perfect Real Time; Takara Bio, Inc., Otsu, Japan) at 37 °C for 30 min and 85 °C for 5 s. qPCR was operated using a 7900 Thermal Cycler (ABI, Applied Biosystems; Thermo Fisher Scientiﬁc, Inc.) with GoTaq® Green Master Mix (Promega Corporation, Madison, WI USA) at an initial denaturation at 95 °C for 30 s, followed by 40 cycles of denaturation for 5 s at 95 °C, annealing for 30 s at 60 °C and extension for 15 s at 72 °C. The qPCR primers were shown as follows: HKII, 5′-GGA CTG GAC CGT CTG AAT GT-3′ (forward) and 5′-ACA GTT CCT TCA CCG TCT GG-3′ (reverse); PFKL, 5′-GGC CGC GGT GGA CCT GGA GAA-3′ (forward) and 5′-TCA GAA GCC CTT GTC CAT GCT CAG G-3′ (reverse); PFKFB1, CCT GCA AAT CAG GAA GCA GT (forward) and TTT GCA AAC TGC AGG ATC AG (reverse); PFKFB2, TAC GAC TTC TTT CCG CAT GA (forward), and CTC CTC TCC CGG GTT GGA TT (reverse); PFKFB3, 5′-CAG TTG TGG CCT CCA ATA TC-3′ (forward) and 5′-GTC TCC ATA GCA ACT GAT CC-3′ (reverse); PKM, TCA TCT CAC AGA CTT CAT GG (forward), GAA GAT GCC AGC TGA CAG GT (reverse). The primers for β-actin were 5′-CAT GTA CGT TGC TAT CCA GGC-3′ (forward) and 5′-TCA CTT ATT AAT GTC ACG CAC GAT-3′ (reverse). The cycle threshold (Cq) values were obtained in each sample. Relative levels of mRNA were measured using the 2^−ΔΔCt method (10). β-actin was used as an internal gene for normalization.

ChIP assay

Cells were ﬁxed with 1% formaldehyde and terminated with 2.5 mM glycine. The scraped cells were sonicated for lysis in PBS with sodium thiocyanate. The lysates were divided into three aliquots, one of which was a positive control and received no treatment and one of which was a
negative control, which was incubated with target protein. One-third of the cell lysate was served as the test group, and was incubated with antibody against MIST1 (1:100) and Protein G PLUS-Agarose. After removal of RNA and protein, DNA was extracted with phenol-chloroform, respectively. Next, the degree of enrichment on gene promoters was detected using real-time quantitative PCR.

Statistical analyses
In vitro experiments were performed with at least three biological replicates based on our preliminary studies. Data are expressed as the mean ± standard deviation. Comparison between different groups was performed using analysis of variance. The Student-Newman-Keuls test was the post-hoc test used following analysis of variance. Data analysis was performed using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA). All reported p values were two-sided, and a value of p < 0.05 was considered statistically significant.

Results
Rev-erba inhibits human gastric cancer cell proliferation
To determine the role of Rev-erba on the proliferation in human gastric cancer cells, we transfected undifferentiated (BGC-823) and moderately differentiated (SGC-7901) gastric cancer cells with Rev-erba siRNAs (Fig. 1a). As shown in Fig. 1b, c, knockdown of Rev-erba gene increased the proliferation of both SGC-7901 and BGC-823 cells. Treatment with a Rev-erba agonist GSK4112 (0.5 μM and 2 μM) for 48 h reduced the proliferation of SGC-7901, BGC-823, and AGS cells in a concentration-dependent manner. Compared to SGC-7901 cells, BGC-823, and AGS cells were not sensitive to GSK4112 (0.5 μM) to reduce cell proliferation (Fig. 1b–d).

Rev-erba reduces glycolysis in human gastric cancer cells
To determine the role of Rev-erba on glycolysis in gastric cancer cells, we measured extracellular acidification rate (ECAR) using Seahorse XF Analyzer in SGC-7901 cells transfected with Rev-erba siRNA. Transfection with Rev-erba siRNA significantly reduced the protein levels of Rev-erba (Fig. 2a). As shown in Fig. 2b, knocking down the Rev-erba gene increased basal glycolysis and glycolytic capacity in SGC-7901 cells. Treatment with a Rev-erba antagonist SR8278 (1 μM and 3 μM) for 48 h significantly increased intracellular levels of lactate in both SGC-7901 and BGC-823 (Fig. 2c). In contrast, treatment with a Rev-erba agonist GSK4112 (0.5 μM and 2 μM, 48 h) reduced glucose consumption in both SGC-7901 and BGC-823 cells (Fig. 2d). Altogether, Rev-erba reduces glycolysis in human gastric cancer cells.

Rev-erba inhibits the expression of genes encoding rate-limiting enzymes in glycolysis
To investigate whether Rev-erba reduces glycolysis by inhibiting the gene encoding rate-limiting enzymes, we transfected Rev-erba siRNA into SGC-7901 cells and detected the expression of HKII, PFK1, PFK2 (PFKFB1, PFKFB2, and PFKFB3 subtype), and PK using quantitative real-time PCR. As shown in Supplementary Fig. 1A, the mRNA levels of PFK1, PFKFB1, PFKFB2, or PK were not altered in SGC-7901 cells transfected with Rev-erba siRNA. However, knockdown of Rev-erba significantly increased the levels of HKII and PFKFB3 genes. Furthermore, chromatin immunoprecipitation was utilized to determine whether Rev-erba is recruited on the promoters of these genes. It was found that Rev-
Rev-erbα was recruited to the promoters of human PFKFB3 but not HKII gene (Supplementary Fig. 1B). These results demonstrate that Rev-erbα is recruited on the promoters of PFKFB3 gene, and suppresses its expression.

**Rev-erbα inhibits G6PD gene expression and NADPH generation**

To investigate whether Rev-erbα regulates the PPP, we transfected Rev-erbα siRNA into SGC-7901 cells and detected the expression of G6PD gene using quantitative real-time PCR. As shown in Supplementary Fig. 2A, knockdown of Rev-erbα significantly increased the levels of G6PD gene. Furthermore, the levels of NADPH were reduced in SGC-7901 cells treated with GSK4112 (0.5–2 μM) for 48 h, and the glucose level in the cell supernatant was measured using a glucose test kit. *P < 0.05, **P < 0.01, ***P < 0.001 vs. Scramble siRNA or vehicle group. Mean ± SEM, N = 4–6.

Rev-erbα has been shown to regulate BMAL1 thereby controlling circadian rhythm. Thus, we determined whether Rev-erbα modulates PFKFB3 and G6PD gene expression by modulating BMAL1. As shown in Supplementary Fig. 3C, BMAL1 gene expression was reduced in SGC-7901 cells when BMAL1 siRNA was transfected. As expected, GSK4112 treatment (2 μM) significantly reduced expression of PFKFB3 and G6PD genes in SGC-7901 cells (Supplementary Fig. 3D, E). However, knockdown of BMAL1 had no effects on PFKFB3 or G6PD gene expression in SGC-7901 cells treated with GSK4112 (2 μM) (Supplementary Fig. 3D and 13E). These results...
demonstrate that Rev-erbα modulates PFKFB3 and G6PD gene expression independent of BMAL1.

Rev-erbα protein inhibits PFKFB3 and G6PD gene expression depending on its DNA binding domain (DBD)

To determine whether the Rev-erbα protein binds directly to the PFKFB3 and G6PD genes, the DBD of Rev-erbα protein was mutated so as to detect PFKFB3 and G6PD gene expression. First, we generated Rev-erbα KO SGC-7901 cells using the CRISPR/Cas9 system (Supplementary Fig. 4A). Next, we transfected the wild-type and mutant DBD plasmids of Rev-erbα in these KO cells, and determined PFKFB3 and G6PD mRNA levels. As shown in Supplementary Fig. 4B, mutation of Rev-erbα DBD significantly increased PFKFB3 and G6PD gene expression in SGC-7901 cells. Hence, Rev-erbα binds to PFKFB3 and G6PD DNA through its DBD.

Rev-erbα inhibits gastric cancer cell proliferation by PFKFB3 and G6PD

Although Rev-erbα inhibited PFKFB3 and G6PD gene expression, it is unclear whether PFKFB3 and G6PD mediate the effect of Rev-erbα on proliferation of human gastric cancer cells. First, Rev-erbα siRNA was transfected into SGC-7901 cells and treated with PFKFB3 and G6PD enzyme inhibitors 3-PO (25 μM) and DHEA (250 μM) for 48 h, respectively. Click-iT EdU cell proliferation assay and flow cytometry were used to detect the incorporation of EdU into DNA. As shown in Fig. 3A, both 3-PO and DHEA significantly reduced Rev-erbα knockdown-induced proliferation in SGC-7901 cells. Combined 3-PO and DHEA treatments further reduced proliferation induced by Rev-erbα knockdown in SGC-7901 cells compared to treatment alone. In contrast, overexpression of PFKFB3 and G6PD increased proliferation in SGC-7901 cells (Fig. 3b). Treatments with a Rev-erbα agonist GSK4112 (2 μM, 48 h) significantly reduced PFKFB3 and G6PD overexpression-induced proliferation in SGC-7901 cells (Fig. 3b). However, GSK4112 treatment did not affect the proliferation of SGC-7901 cells induced by dual overexpression of PFKFB3 and G6PD (Fig. 3b). These results suggest that Rev-erbα inhibits proliferation of human gastric cancer cells via downstream PFKFB3 and G6PD signaling.

Glycolysis and the PPP are enhanced in patients with low expression of Rev-erbα in gastric cancer tissues

To extrapolate the in vitro findings into human samples, we determine the expression of PFKFB3 and G6PD as well as the metabolites, including lactate, pyruvate and NADPH in patients with gastric cancer. As shown in Supplementary Fig. 5A, the protein abundance of PFKFB3 and G6PD was increased in gastric cancer tissues, which was associated with increased TNM stage. This was confirmed by immunohistochemistry (Supplementary Fig. 5B). We next grouped the patients with gastric cancer into low and high expression of Rev-erbα, as previously described.16 We found that the mRNA levels of PFKFB3 and G6PD were augmented in patients with low abundance of Rev-erbα (Fig. 4a). Furthermore, the levels of lactate and NADPH were also increased in patients with low expression of Rev-erbα compared to the patients with high expression of Rev-erbα (Fig. 4b). The levels of pyruvate were not changed in patients with gastric cancer between low and high expression of Rev-erbα (Fig. 4c). Altogether, these results suggest that low expression of Rev-erbα associates with increased glycolysis and the PPP in gastric cancer.

Discussion

We have shown that Rev-erbα was reduced in human gastric cancer, which was associated with poor differentiation, TMN stages and poor prognosis.16 However,
the mechanisms underlying these findings are not clear. In the present study, we found that Rev-erbα inhibits glycolysis and the PPP, thereby reducing proliferation in gastric cancer cells. This was due to increased expression of PFKFB3 and G6PD in human gastric cancer cells. Moreover, reduced Rev-erbα in patients with gastric cancer correlated with increased glycolysis and the PPP in cancer tissues. These findings provide potential therapeutic approaches by activating Rev-erbα to inhibit the proliferation of gastric cancer cells.

Rev-erbα is highly expressed in adipose tissue, skeletal muscle and brain, which plays important roles in lipid metabolism, adipocyte differentiation, inflammatory response, and circadian rhythm. Although heme, a ligand of Rev-erbα, inhibits the expression of phosphoenolpyruvate carboxykinase involved in gluconeogenesis, there are no reports regarding the role of Rev-erbα in glycolysis and the PPP. There are three rate-limiting enzymes, including HKII, PFK, and PK, in glycolysis and a rate-limiting enzyme G6PD in the PPP. We found that Rev-erbα could be recruited on the promoters of PFKFB3, an isoform of PFK, and G6PD genes, and directly inhibited their gene transcription in human gastric cancer cells. Along with the data on ECAR, lactate, and glucose consumption, Rev-erbα suppresses glycolytic flux and the PPP in gastric cancer cells by inhibiting PFKFB3 and G6PD gene expression. There are two pathways for Rev-erbα-mediated transcription repression. Once in nucleus, Rev-erbα competes with the retinoic acid-associated orphan receptor alpha (RORA) to bind with the ROR response element (RORE) of targeting genes, such as circadian gene Bmal1, inhibiting their transcription. However, we found that knockdown of Bmal1 did not influence PFKFB3 or G6PD gene expression when cells were treated with GSK4112. These findings suggest that BMAL1 is not involved in Rev-erbα-mediated modulation on PFKFB3 or G6PD gene expression in gastric cancer cells. In the present study, we showed that PFKFB3 and G6PD genes did not exhibit rhythmic expression. This is not in agreement with the finding that the expression of these genes is rhythmic in tongue cancer cells. This discrepancy may be due to cell-specific (gastric vs tongue cancer cells). The second pathway is that that Rev-erbα inhibits gene transcription by directly binding to target response elements (RevREs) and by recruiting the corepressor N-CoR and histone deacetylases on targeting gene promoters. It remains elusive whether Rev-erbα inhibits PFKFB3 and G6PD gene expression using similar mechanisms in human gastric cancer cells.

It has been shown that Rev-erbα binds to the genome using both DBD-dependent and DBD-independent mechanisms. We found that mutation of Rev-erbα DBD domain increased the mRNA levels of PFKFB3 and G6PD in human gastric cancer cell. This suggest that Rev-erbα relies on its DBD, thereby inhibiting PFKFB3 and G6PD gene expression. Further study is required to determine on the mechanisms of increased HKII gene expression once Rev-erbα was knocked down, despite Rev-erbα was not recruited on HKII gene promoters.

The glycolysis and its parallel shunt PPP not only generate bioenergetics for meeting the demands of malignant cell growth, but also provide a variety of biosynthesis of macromolecules for their anabolism. This was corroborated by our findings that pharmacological inhibition of glycolysis and the PPP reduced proliferation in gastric cancer cells, whereas overexpression of PFKFB3 and G6PD augmented proliferation in these cells. In addition, inhibition of PFKFB3 and G6PD significantly attenuated Rev-erbα knockdown-induced increase in proliferation. These finding suggest that Rev-erbα inhibits proliferation in gastric cancer cells by suppressing PFKFB3 and G6PD gene expression. It is interesting to note that GSK4412-mediated inhibition of proliferation was abolished in dual PFKFB3 and G6PD overexpressing cells but not in individual overexpressing cells. This suggests that both PFKFB3 and G6PD are required for proliferation when Rev-erbα was reduced in human gastric cancer cells.

Utilizing clinical human samples, we found that the protein abundance of PFKFB3 and G6PD was increased in patients with gastric cancer. Furthermore, this was
associated with increased TNM stage of human gastric cancer. This is corroborated by the findings that both PFKFB3 and G6PD are overexpressed in patients with gastric cancer, and promoted the proliferation and migration of gastric cancer cells. It is interesting to note that the PPP and glycolysis were enhanced in human gastric cancer with low expression of Rev-erba compared to gastric cancer tissues with high expression of Rev-erba. These findings further confirmed that Rev-erba is reduced in gastric cancer, which leads to proliferation by promoting the PPP and glycolysis in gastric cancer cells.

In summary, we demonstrated for the first time that Rev-erba was recruited to promoters of PFKFB3 and G6PD genes, thereby inhibiting glycolytic flux and the PPP, and subsequent proliferation in in vitro human gastric cancer cells. Furthermore, the PPP and glycolysis were enhanced in gastric cancer patients with low expression of Rev-erba compared to gastric cancer tissues with high expression of Rev-erba. Therefore, our findings provide a new biomarker and promising therapeutic strategy for the treatment of gastric carcinoma by targeting Rev-erba-mediated metabolic reprogramming.

Acknowledgements
The present study was funded by the Natural Science Foundation of Anhui Province (grant no. 1608085MH182).

Authors’ contributions
LT, H.Y., and Z.W. conceived and performed the experiments, L.T., H.Y., R.L., R.J., J.W., and K.J. performed the experiments, and analyzed the data. L.T., H.Y., and Z.W. wrote and edited the manuscript.

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information
accompanies this paper at (https://doi.org/10.1038/s41389-019-0166-3).

Received: 21 March 2019 Revised: 23 September 2019 Accepted: 24 September 2019
Published online: 07 October 2019

References
1. Jemal, A. et al. Global cancer statistics. CA: a cancer J. Clinics. 61, 69–90 (2011).
2. Sitarz, R. et al. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag. Res. 10, 239–246 (2018).
3. Han, J., Meng, Q., Xi, Q., Wang, H., & Wu, G. PFKFB3 was overexpressed in gastric cancer patients and promoted the proliferation and migration of gastric cancer cells. Cancer Biomark. 18, 249–256 (2017).
4. Hur, H. et al. Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target. Int. J. Oncol. 42, 44–54 (2013).
5. Qiu, M. Z. et al. Expressions of hypoxia-inducible factor-alpha and hexokinase-II in gastric adenocarcinoma: the impact on prognosis and correlation with clinicopathological features. Tumour Biol. 32, 159–166 (2011).
6. Shimada, Y. et al. Glucose transporter 3 and 1 may facilitate high uptake of 18F-FDG in gastric schwannoma. Clin. Nucl. Med. 38, e417–e420 (2013).
7. Wang, J. et al. Overexpression of G6PD is associated with poor clinical outcome in gastric cancer. Tumour Biol. 33, 95–101 (2012).
8. Wang, T. A., Xian, S. L., Guo, X. Y., Zhang, X. D. & Lu, Y. F. Combined 18F-FDG PET/CT imaging and a gastric orthotopic xenograft model in nude mice are used to evaluate the efficacy of glycolysis-targeted therapy. Oncol. Rep. 39, 271–279 (2018).
9. Yamada, A., Oguchi, K., Fukushima, M., Imai, Y. & Kadoya, M. Evaluation of 2-deoxy-x-[18F]fluoro-D-glucose positron emission tomography in gastric carcinomas relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Ann. Nucl. Med. 20, 597–604 (2006).
10. Yin, L. et al. The value of expression of M2-PR and VEGF in patients with advanced gastric cancer. Genet. Mol. Res. 12, 1013–1039 (2013).
11. Hu, D. et al. Preoperative metabolic syndrome is predictive of significant gastric cancer mortality after gastrectomy: The Fujian Prospective Investigation of Cancer (FIESTA) Study. ElioMedicine 15, 73–80 (2017).
12. Kojentin, D. J. & Burris, T. P. REV-ERB and ROR nuclear receptors as drug targets. Nat. Rev. Drug Discov. 13, 197–216 (2014).
13. Sull, G. et al. Pharmacological activation of REV-ERBs is lethal in cancer and cancer stem cells. Oncogene 34, 2597–2608 (2015).
14. Wang, Y., Kojentin, D. J. & Burris, T. P. Anti-proliferative actions of a synthetic REV-ERBalpha/beta agonist in breast cancer cells. Biochem. Pharmacol. 96, 315–322 (2015).
15. Wang, X., Wang, N., Wei, X., Yu, H. & Wang, Z. REV-ERBalpha reduction is associated with clinicopathological features and prognosis in human gastric cancer. Oncol. Lett. 16, 1499–1506 (2018).
16. Grundschöber, C. et al. Circadian regulation of diverse gene products revealed by mRNA expression profiling of synchronized fibroblasts. J. Biol. Chem. 276, 46751–46758 (2001).
17. Moore, S. R. et al. Robust circadian rhythms in organoid cultures from PERIOD2:LUCCERASE mouse small intestine. Dis. Model Mech. 7, 1123–1130 (2014).
18. Burgess, D. J. Technology: a CRISPR genome-editing tool. Nat. Rev. Genet. 14, 80 (2013).
19. Shalem, O. et al. Genome-scale CRISPR Cas9 screening in human cells. Science 341, 84–87 (2014).
20. Zhang, Y. et al. GENE REGULATION. Discrete functions of nuclear receptor Rev-erba and Ror-1 couple metabolism to the clock. Science 348, 1488–1492 (2015).
21. Wang, Z. et al. Nuclear receptor retinoid-related orphan receptor alpha promotes apoptosis but is reduced in human gastric cancer. Oncotarget 8, 11105–11113 (2017).
22. Yao, H. et al. Fatty acid oxidation protects against hyperoxia-induced endothelial cell apoptosis and lung injury in neonatal mice. Am. J. Respir. Cell Mol. Biol. 60, 667–677 (2019).
23. Pike Winer, L. S. & Wu, M. Rapid analysis of glycolytic and oxidative substrate flux of cancer cells in a microplate. PLoS ONE 9, e109916 (2014).
24. Wu, Y. et al. AMPK activator AICAR promotes 5-FU-induced apoptosis in gastric cancer cells. Mol. Cell. Biochem. 411, 299–315 (2016).
25. Chen, L. et al. PFKFB3 control of cancer growth by responding to circadian clock outputs. Sci. Rep. 6, 24324 (2016).
26. Soler, G., Bautista, J. M., Madrid, J. A. & Salido, G. M. Circadian rhythms in enzymatic activity of rat liver arginase and glucose 6-phosphate dehydrogenase. Chronobiologia 15, 205–212 (1988).
27. Cho, H. et al. Regulation of circadian behaviour and metabolism by REV-ERB-alpha and REV-ERB-beta. Nature 485, 123–127 (2012).
28. Vieira, E., Merino, B. & Querad, I. Role of the clock gene Rev-erba in metabolism and in the endocrine pancreas. Diabetes Obes. Metab. 17(Suppl 1), 106–114 (2015).
29. Yin, L. et al. Rev-erba, a home sensor that coordinates metabolic and circadian pathways. Science 318, 1786–1789 (2007).
30. Guillaumond, F., Dardente, H., Giugere, V. & Cermakian, N. Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors. J. Biol. Rhythms 20, 391–403 (2005).
31. Preitner, N. et al. The orphan nuclear receptor REV-ERB alpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell 110, 251–260 (2002).
32. Jetten, A. M., Kang, H. S. & Takada, Y. Retinoid acid-related orphan receptors alpha and gamma: key regulators of lipid/glucose metabolism, inflammation, and insulin sensitivity. Front. Endocrinol. 4, 1 (2013).